Skip Navigation


Japanese Journal of Clinical Oncology Advance Access originally published online on January 24, 2009
Japanese Journal of Clinical Oncology 2009 39(3):183-185; doi:10.1093/jjco/hyn146
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Supplementary Data
Right arrow All Versions of this Article:
39/3/183    most recent
hyn146v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (1)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Lee, J.-O.
Right arrow Articles by Lee, J. S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Lee, J.-O.
Right arrow Articles by Lee, J. S.
Related Collections
Right arrow Case Report
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?


© The Author (2009). Published by Oxford University Press. All rights reserved

Metastatic Adrenocortical Carcinoma Treated with Sunitinib: A Case Report

Jeong-Ok Lee1, Keun-Wook Lee1, Chung-Jong Kim1, Yu Jung Kim1, Hee Eun Lee2, Haeryoung Kim2, Jee Hyun Kim1, Soo-Mee Bang1, Jae-Sung Kim3 and Jong Seok Lee1

1 Department of Internal Medicine
2 Department of Pathology
3 Department of Radiation Oncology, Seoul National University Bundang Hospital, Seongnam, Republic of Korea

For reprints and all correspondence: Keun-Wook Lee, Department of Internal Medicine, Seoul National University Bundang Hospital, 300 Gumi-dong, Bundang-gu, Seongnam-si, Gyeongi-do 463-707, Republic of Korea. E-mail: hmodoctor{at}hanmail.net

Received July 30, 2008; accepted November 30, 2008

Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis. Palliative chemotherapy can be considered in patients with metastatic disease. Although mitotane- or cisplatin-based chemotherapy regimens are widely used, the effects of these agents have been limited. We have experienced a case that showed a partial response with sunitinib after failure of mitotane-based cytotoxic chemotherapy. The clinical benefit from sunitinib persisted 7.5 months in this case. To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.

Key Words: adrenocortical carcinoma • chemotherapy • sunitinib


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.